President Jokowi Inspects Administration of First IndoVac Vaccine Jab

President Jokowi inspects the administration of the first IndoVac vaccine jab at PT Bio Farma (Persero) in Bandung, Thursday (10/13). (Photo by: BPMI of Presidential Secretariat/Laily Rachev)

Following the launching of IndoVac COVID-19 vaccine, President Joko “Jokowi” Widodo, Thursday (10/13), inspected the administration of the first vaccine jab at PT Bio Farma (Persero) in West Java provincial capital Bandung.

Upon arrival at the vaccination location, President Jokowi checked the packaging of IndoVac vaccine, then witnessed healthcare workers administer the vaccine injection to recipients.

For the record, IndoVac vaccine is a recombinant protein subunit vaccine manufactured by state-owned pharmaceutical company PT Bio Farma. The company carried out COVID-19 vaccine research and development from November 2021 to September 2022.

IndoVac vaccine has obtained emergency use authorization (EUA) from the Food and Drug Authority (BPOM) on September 24 for primary vaccination, namely doses one and two for adults (18 years old and above).

IndoVac has also received halal status from the Indonesian Ulema Council (MUI).

PT Bio Farma has implemented good governance throughout the production process as it obtained Good Manufacturing Practice (GMP) certificate from the BPOM and has carried out preclinical trials on animals, stage I clinical trials on 175 subjects, stage II clinical trials on 360 subjects, and stage III clinical trials on 4,050 subjects.

The clinical trials showed that the vaccine is safe and has low-intensity vaccination side effects, such as sore on the injection area. The vaccine also has good effectiveness in increasing antibody titer.

Meanwhile, the immunobridging trial involving a comparator vaccine with efficacy above 80 percent resulted in IndoVac’s non-inferiority, which means that IndoVac has better effectiveness than the comparator. (BPMI of Presidential Secretariat/UN) (DH/MMB)